[go: up one dir, main page]

MA32627B1 - Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase - Google Patents

Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase

Info

Publication number
MA32627B1
MA32627B1 MA33690A MA33690A MA32627B1 MA 32627 B1 MA32627 B1 MA 32627B1 MA 33690 A MA33690 A MA 33690A MA 33690 A MA33690 A MA 33690A MA 32627 B1 MA32627 B1 MA 32627B1
Authority
MA
Morocco
Prior art keywords
heteroarylic
amide derivative
glucokinase activators
glucokinase
activators
Prior art date
Application number
MA33690A
Other languages
Arabic (ar)
English (en)
Inventor
John William Benbow
Jihong Lou
Jeffrey Allen Pfefferkorn
Meihua Mike Tu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228587&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32627(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MA32627B1 publication Critical patent/MA32627B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur des composés de formule (1a) qui servent d'activateurs de la glucokinase; sur des compositions pharmaceutiques de ceux-ci; et sur des procédés de traitement de maladies, de troubles, ou d'affections à médiation par la glucokinase. X, y, z, r1, r2, r3 et r4 sont tels que spécifiés dans la description.
MA33690A 2008-09-11 2011-03-11 Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase MA32627B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9605608P 2008-09-11 2008-09-11
US23257809P 2009-08-10 2009-08-10
PCT/IB2009/053773 WO2010029461A1 (fr) 2008-09-11 2009-08-28 Dérivés d'amides d'hétéroaryles et leur utilisation comme activateurs de la glucokinase

Publications (1)

Publication Number Publication Date
MA32627B1 true MA32627B1 (fr) 2011-09-01

Family

ID=41228587

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33690A MA32627B1 (fr) 2008-09-11 2011-03-11 Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase

Country Status (29)

Country Link
US (4) US7977367B2 (fr)
EP (1) EP2344458A1 (fr)
JP (2) JP4907746B2 (fr)
KR (1) KR101258331B1 (fr)
CN (1) CN102216276A (fr)
AP (1) AP2011005613A0 (fr)
AR (1) AR073283A1 (fr)
AU (1) AU2009290474A1 (fr)
BR (1) BRPI0918128A2 (fr)
CA (1) CA2735184C (fr)
CL (1) CL2011000478A1 (fr)
CO (1) CO6361937A2 (fr)
CR (1) CR20110103A (fr)
DO (1) DOP2011000076A (fr)
EA (1) EA201100311A1 (fr)
EC (1) ECSP11010885A (fr)
GE (1) GEP20135793B (fr)
IL (1) IL211411A0 (fr)
MA (1) MA32627B1 (fr)
MX (1) MX2011002613A (fr)
NI (1) NI201100050A (fr)
NZ (1) NZ591366A (fr)
PA (1) PA8842101A1 (fr)
PE (1) PE20110303A1 (fr)
SV (1) SV2011003855A (fr)
TW (1) TWI382026B (fr)
UY (1) UY32098A (fr)
WO (1) WO2010029461A1 (fr)
ZA (1) ZA201101364B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2454229B1 (fr) * 2009-05-06 2017-09-13 Risen (Shanghai) Pharma Tech Co, Ltd. Dérivés d'acide aminé pour le traitement de la douleur neuropathique
EP3936608B1 (fr) 2010-03-31 2025-05-07 The Scripps Research Institute Reprogrammation de cellules
CN103201269A (zh) * 2010-11-11 2013-07-10 赛诺菲 3-(6-氨基-吡啶-3基)-2-丙烯酸衍生物的制备方法
IN2014DN07224A (fr) 2012-02-03 2015-04-24 Basf Se
WO2013113773A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés fongicides de pyrimidine
WO2013113787A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides
WO2013113781A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides i
WO2013113776A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides
WO2013113782A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides
WO2013113716A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides
EA201491472A1 (ru) 2012-02-03 2015-01-30 Басф Се Фунгицидные соединения пиримидина
WO2013113719A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides ii
IN2014DN07954A (fr) 2012-03-13 2015-05-01 Basf Se
WO2013135672A1 (fr) 2012-03-13 2013-09-19 Basf Se Composés de pyrimidine fongicides
MA37825B1 (fr) 2012-07-04 2016-06-30 Agro Kanesho Co Ltd Dérivé d'ester d'acide 2-aminonicotinique et bactéricide le contenant comme principe actif
WO2014142255A1 (fr) 2013-03-14 2014-09-18 武田薬品工業株式会社 Composé hétérocyclique
JP6411342B2 (ja) 2013-07-03 2018-10-24 武田薬品工業株式会社 アミド化合物
JP6427491B2 (ja) 2013-07-03 2018-11-21 武田薬品工業株式会社 複素環化合物
EP2878339A1 (fr) 2013-12-02 2015-06-03 Siena Biotech S.p.A. Antagonistes SIP3
AR099677A1 (es) 2014-03-07 2016-08-10 Sumitomo Chemical Co Compuesto heterocíclico fusionado y su uso para el control de plagas
EP3487862A1 (fr) 2016-07-22 2019-05-29 Bristol-Myers Squibb Company Activateurs de glucokinase et leurs procédés d'utilisation
TW201840578A (zh) * 2017-02-22 2018-11-16 以色列商亞當阿甘公司 製備甲基膦酸丁基酯的方法
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
CN109134535B (zh) * 2018-10-22 2021-03-19 江苏长青农化股份有限公司 一种甲基磷酸酯的制备方法
CA3191078A1 (fr) * 2020-08-25 2022-03-03 Christian Ducho Inhibiteurs du facteur de virulence de lasb de pseudomonas aeruginosa
IL308096A (en) 2021-07-08 2023-12-01 Ishihara Sangyo Kaisha Nematicidal compound

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5795984A (en) 1980-12-05 1982-06-15 Tanabe Seiyaku Co Ltd Pyridinecarboxamide derivative and its preparation
US5399564A (en) 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
EP0606489A4 (fr) 1992-07-03 1995-01-25 Kumiai Chemical Industry Co Derive heterocyclique condense et desherbant.
AU702346B2 (en) 1994-07-22 1999-02-18 Altana Pharma Ag Dihydrobenzofuranes
DE4434637A1 (de) 1994-09-28 1996-04-04 Hoechst Schering Agrevo Gmbh Substituierte Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
CN1166834A (zh) 1994-10-13 1997-12-03 美国辉瑞有限公司 苯并吡喃和苯并稠合化合物，其制备方法和它们作为白三烯b4(ltb4)拮抗剂的用途
NZ285156A (en) 1994-10-13 1999-01-28 Pfizer Benzopyran and benzo-fused compounds, preparation and use as leukotriene b4 antagonists (ltb4)
DE19603576A1 (de) 1996-02-01 1997-08-07 Bayer Ag Acylierte 4-Amino und 4-Hydrazinopyrimidine
US5972936A (en) 1996-05-20 1999-10-26 Darwin Discover Limited Benzofuran carboxamides and their therapeutic use
DK0923568T5 (da) 1996-08-19 2003-11-03 Altana Pharma Ag Hidtil ukendte benzofuran-4-carboxamider
AU2529799A (en) 1998-02-09 1999-08-23 Darwin Discovery Limited Benzofuran-4-carboxamides and their therapeutic use
ATE455106T1 (de) 1999-01-22 2010-01-15 Elan Pharm Inc Acyl derivate zur behandlung von krankheiten die in zusammenhang mit vla-4 stehen
SE9901573D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds
WO2002020463A2 (fr) 2000-09-05 2002-03-14 Tularik Inc. Modulateurs fxr
CA2436854A1 (fr) 2000-11-20 2002-05-23 Bristol-Myers Squibb Company Derives de pyridones utilises en tant qu'inhibiteurs ap2
DE60117059T2 (de) * 2000-12-06 2006-10-26 F. Hoffmann-La Roche Ag Kondensierte heteroaromatische glucokinaseaktivatoren
US6482951B2 (en) * 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
JPWO2002051836A1 (ja) 2000-12-27 2004-04-22 協和醗酵工業株式会社 ジペプチジルペプチダーゼ−ｉｖ阻害剤
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
JP4623962B2 (ja) 2001-10-22 2011-02-02 ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク タンパク質キナーゼおよびホスファターゼ阻害剤、それらを設計する方法、ならびにそれらを使用する方法
ATE448784T1 (de) 2002-02-14 2009-12-15 Pharmacia Corp Substituierte pyridinone als modulatoren für p38 map kinase
CN100357283C (zh) 2002-04-02 2007-12-26 中国科学院上海药物研究所 一类甲硫氨酰氨肽酶抑制剂
WO2003092670A1 (fr) 2002-05-03 2003-11-13 Warner-Lambert Company Llc Antagonistes de bombesine
JP4287816B2 (ja) 2002-06-13 2009-07-01 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー ピラゾールカルボキサミド殺虫剤
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
EP1433778A1 (fr) 2002-12-23 2004-06-30 Jerini AG Utilisation de nitriles en tant qu'inhibiteurs de rotamase
WO2004072066A1 (fr) * 2003-02-11 2004-08-26 Prosidion Limited Composes d'amide a substitution tri(cyclo), activateurs de la glucokinase
UA82867C2 (en) 2003-02-13 2008-05-26 Banyu Pharma Co Ltd 2-pyridinecarboxamide derivatives
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
KR20050105488A (ko) 2003-02-26 2005-11-04 반유 세이야꾸 가부시끼가이샤 헤테로아릴카바모일벤젠 유도체
US20060205751A1 (en) 2003-07-15 2006-09-14 Smithkline Beecham Corporation Novel compounds
CA2533747C (fr) 2003-08-01 2012-11-13 Chugai Seiyaku Kabushiki Kaisha Composes heterocycliques utiles comme inhibiteurs de la malonyl-coa decarboxylase
NL1026826C2 (nl) 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
EP1532980A1 (fr) * 2003-11-24 2005-05-25 Novo Nordisk A/S Carboxamides d'indole n-heteroarylé et leurs analogues, utiles comme des activateurs de glucokinase pour le traitement de diabetes
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
PT1735322E (pt) * 2004-04-02 2012-01-12 Novartis Ag Derivados de sulfonamido-tiazolopiridina como activadores de glucoquinase úteis para o tratamento de diabetes de tipo 2
WO2006015159A2 (fr) 2004-07-29 2006-02-09 Merck & Co., Inc. Inhibiteurs de canal a potassium
EP1786783A1 (fr) 2004-09-01 2007-05-23 Rigel Pharmaceuticals, Inc. Synthese de composes de 2,4-pyrimidinediamine
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
SE0403006D0 (sv) 2004-12-09 2004-12-09 Biovitrum Ab New compounds
PL1831191T3 (pl) 2004-12-21 2008-10-31 Hoffmann La Roche Pochodne chromanu i ich zastosowanie jako ligandów receptorów 5-HT
JP4167218B2 (ja) 2004-12-22 2008-10-15 株式会社メタル建材 薄板用タッピンねじ
TW200700392A (en) 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
US20090275570A1 (en) 2005-04-06 2009-11-05 Astrazeneca Ab Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
AU2006285834A1 (en) 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
JP2009013065A (ja) 2005-10-14 2009-01-22 Astellas Pharma Inc 縮合へテロ環化合物
CN101360720A (zh) 2005-11-15 2009-02-04 阿斯利康(瑞典)有限公司 新颖的2-氨基嘧啶酮衍生物及其用途
JP5302012B2 (ja) 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
WO2007117995A2 (fr) 2006-03-30 2007-10-18 Takeda San Diego, Inc. Inhibiteurs de kinase
US7842713B2 (en) 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
WO2008079787A2 (fr) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Activateurs de glucokinase
JP2010138073A (ja) 2007-03-30 2010-06-24 Taisho Pharmaceutical Co Ltd ピコリン酸アミド化合物
US8299115B2 (en) 2007-06-08 2012-10-30 Debnath Bhuniya Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
UY31830A (es) * 2008-05-16 2010-01-05 Takeda Pharmaceutical Activadores de glucoquinasa
JP2012515760A (ja) 2009-01-20 2012-07-12 ファイザー・インク 置換ピラジノンアミド

Also Published As

Publication number Publication date
JP4907746B2 (ja) 2012-04-04
CL2011000478A1 (es) 2011-06-17
JP2012502091A (ja) 2012-01-26
KR101258331B1 (ko) 2013-04-26
MX2011002613A (es) 2011-05-23
GEP20135793B (en) 2013-03-25
KR20110043748A (ko) 2011-04-27
US8329920B2 (en) 2012-12-11
AP2011005613A0 (en) 2011-04-30
AU2009290474A1 (en) 2010-03-18
DOP2011000076A (es) 2011-03-31
CA2735184A1 (fr) 2010-03-18
NZ591366A (en) 2012-05-25
ECSP11010885A (es) 2011-04-29
AR073283A1 (es) 2010-10-28
SV2011003855A (es) 2011-05-16
ZA201101364B (en) 2012-04-25
US7977367B2 (en) 2011-07-12
NI201100050A (es) 2011-09-27
CO6361937A2 (es) 2012-01-20
WO2010029461A1 (fr) 2010-03-18
BRPI0918128A2 (pt) 2015-11-24
UY32098A (es) 2010-04-30
US20130165452A1 (en) 2013-06-27
US20110230445A1 (en) 2011-09-22
US20120225910A1 (en) 2012-09-06
PE20110303A1 (es) 2011-05-21
CN102216276A (zh) 2011-10-12
CR20110103A (es) 2011-03-14
US8389552B2 (en) 2013-03-05
EP2344458A1 (fr) 2011-07-20
PA8842101A1 (es) 2010-04-21
JP5225452B2 (ja) 2013-07-03
JP2012092115A (ja) 2012-05-17
EA201100311A1 (ru) 2011-10-31
TW201010998A (en) 2010-03-16
CA2735184C (fr) 2013-05-28
US20100063063A1 (en) 2010-03-11
TWI382026B (zh) 2013-01-11
IL211411A0 (en) 2011-05-31

Similar Documents

Publication Publication Date Title
MA32627B1 (fr) Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase
MA31087B1 (fr) Derives d'amide et d'ester d'indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde.
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA31373B1 (fr) Composes amino-heterocycliques
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
MA47043B1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MY146662A (en) Novel n-(8-heteroaryltetrahydronaphtalene-2yl) or n-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
MA31683B1 (fr) Composes et procedes pour moduler fxr
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
EP2037739A4 (fr) Effecteurs allostériques positifs du récepteur m1 à base de quinolone à substitution benzyle
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes